Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung

Carlos Bermúdez, Juan Pérez-Wulff, Mauricio Arcadipane, Gesualdo Bufalino, Libardo Gómez, Luis Flores, Cristian Sosa, Patricia W. Bornick, Eftichia Kontopoulos, Rubén A. Quintero

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives: Congenital cystic adenomatoid malformation (CCAM) is a rare lesion of the developing fetal lung consisting of increased cell proliferation in the bronchial structures with lack of differentiation of the alveoli. Pregnancies may be at an increased risk for perinatal loss with type III CCAM. The purpose of this paper is to present our experience with the management of complicated types II and III CCAM with a novel technique: percutaneous ultrasound-guided fetal sclerotherapy (FST). Methods: Three patients were referred with type II-III CCAM. Poor prognostic factors included hydrops, severe mediastinal shift, polyhydramnios and early gestational age (<26 weeks). Patients signed an informed consent. FST was performed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aethoxysklerol) under ultrasound guidance using a 22-gauge needle. Results: Resolution of hydrops and of the mass effect was observed in all cases without any complications. All patients were delivered at term. Conclusions: Fetal sclerotherapy is a novel approach to the management of complicated type II-III CCAM. Further studies are indicated to assess the risks and benefits of this innovative technique.

Original languageEnglish
Pages (from-to)237-240
Number of pages4
JournalFetal Diagnosis and Therapy
Volume24
Issue number3
DOIs
StatePublished - Oct 1 2008

Fingerprint

Congenital Cystic Adenomatoid Malformation of Lung
Sclerotherapy
Edema
Polyhydramnios
Informed Consent
Gestational Age
Needles
Cell Proliferation
Pregnancy
Lung
Injections

Keywords

  • Cystic congenital adenomatoid malformation
  • Ethamolin (ethanolamine oleate)
  • Fetal hydrops
  • Fetal therapy
  • Lung mass
  • Polidocanol (aethoxysklerol)
  • Ultrasound

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Radiology Nuclear Medicine and imaging

Cite this

Bermúdez, C., Pérez-Wulff, J., Arcadipane, M., Bufalino, G., Gómez, L., Flores, L., ... Quintero, R. A. (2008). Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. Fetal Diagnosis and Therapy, 24(3), 237-240. https://doi.org/10.1159/000151345

Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. / Bermúdez, Carlos; Pérez-Wulff, Juan; Arcadipane, Mauricio; Bufalino, Gesualdo; Gómez, Libardo; Flores, Luis; Sosa, Cristian; Bornick, Patricia W.; Kontopoulos, Eftichia; Quintero, Rubén A.

In: Fetal Diagnosis and Therapy, Vol. 24, No. 3, 01.10.2008, p. 237-240.

Research output: Contribution to journalArticle

Bermúdez, C, Pérez-Wulff, J, Arcadipane, M, Bufalino, G, Gómez, L, Flores, L, Sosa, C, Bornick, PW, Kontopoulos, E & Quintero, RA 2008, 'Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung', Fetal Diagnosis and Therapy, vol. 24, no. 3, pp. 237-240. https://doi.org/10.1159/000151345
Bermúdez C, Pérez-Wulff J, Arcadipane M, Bufalino G, Gómez L, Flores L et al. Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. Fetal Diagnosis and Therapy. 2008 Oct 1;24(3):237-240. https://doi.org/10.1159/000151345
Bermúdez, Carlos ; Pérez-Wulff, Juan ; Arcadipane, Mauricio ; Bufalino, Gesualdo ; Gómez, Libardo ; Flores, Luis ; Sosa, Cristian ; Bornick, Patricia W. ; Kontopoulos, Eftichia ; Quintero, Rubén A. / Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung. In: Fetal Diagnosis and Therapy. 2008 ; Vol. 24, No. 3. pp. 237-240.
@article{20aaf2356c5f4cdab67ce2fa885da9f4,
title = "Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung",
abstract = "Objectives: Congenital cystic adenomatoid malformation (CCAM) is a rare lesion of the developing fetal lung consisting of increased cell proliferation in the bronchial structures with lack of differentiation of the alveoli. Pregnancies may be at an increased risk for perinatal loss with type III CCAM. The purpose of this paper is to present our experience with the management of complicated types II and III CCAM with a novel technique: percutaneous ultrasound-guided fetal sclerotherapy (FST). Methods: Three patients were referred with type II-III CCAM. Poor prognostic factors included hydrops, severe mediastinal shift, polyhydramnios and early gestational age (<26 weeks). Patients signed an informed consent. FST was performed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aethoxysklerol) under ultrasound guidance using a 22-gauge needle. Results: Resolution of hydrops and of the mass effect was observed in all cases without any complications. All patients were delivered at term. Conclusions: Fetal sclerotherapy is a novel approach to the management of complicated type II-III CCAM. Further studies are indicated to assess the risks and benefits of this innovative technique.",
keywords = "Cystic congenital adenomatoid malformation, Ethamolin (ethanolamine oleate), Fetal hydrops, Fetal therapy, Lung mass, Polidocanol (aethoxysklerol), Ultrasound",
author = "Carlos Berm{\'u}dez and Juan P{\'e}rez-Wulff and Mauricio Arcadipane and Gesualdo Bufalino and Libardo G{\'o}mez and Luis Flores and Cristian Sosa and Bornick, {Patricia W.} and Eftichia Kontopoulos and Quintero, {Rub{\'e}n A.}",
year = "2008",
month = "10",
day = "1",
doi = "10.1159/000151345",
language = "English",
volume = "24",
pages = "237--240",
journal = "Fetal Diagnosis and Therapy",
issn = "1015-3837",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Percutaneous fetal sclerotherapy for congenital cystic adenomatoid malformation of the lung

AU - Bermúdez, Carlos

AU - Pérez-Wulff, Juan

AU - Arcadipane, Mauricio

AU - Bufalino, Gesualdo

AU - Gómez, Libardo

AU - Flores, Luis

AU - Sosa, Cristian

AU - Bornick, Patricia W.

AU - Kontopoulos, Eftichia

AU - Quintero, Rubén A.

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Objectives: Congenital cystic adenomatoid malformation (CCAM) is a rare lesion of the developing fetal lung consisting of increased cell proliferation in the bronchial structures with lack of differentiation of the alveoli. Pregnancies may be at an increased risk for perinatal loss with type III CCAM. The purpose of this paper is to present our experience with the management of complicated types II and III CCAM with a novel technique: percutaneous ultrasound-guided fetal sclerotherapy (FST). Methods: Three patients were referred with type II-III CCAM. Poor prognostic factors included hydrops, severe mediastinal shift, polyhydramnios and early gestational age (<26 weeks). Patients signed an informed consent. FST was performed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aethoxysklerol) under ultrasound guidance using a 22-gauge needle. Results: Resolution of hydrops and of the mass effect was observed in all cases without any complications. All patients were delivered at term. Conclusions: Fetal sclerotherapy is a novel approach to the management of complicated type II-III CCAM. Further studies are indicated to assess the risks and benefits of this innovative technique.

AB - Objectives: Congenital cystic adenomatoid malformation (CCAM) is a rare lesion of the developing fetal lung consisting of increased cell proliferation in the bronchial structures with lack of differentiation of the alveoli. Pregnancies may be at an increased risk for perinatal loss with type III CCAM. The purpose of this paper is to present our experience with the management of complicated types II and III CCAM with a novel technique: percutaneous ultrasound-guided fetal sclerotherapy (FST). Methods: Three patients were referred with type II-III CCAM. Poor prognostic factors included hydrops, severe mediastinal shift, polyhydramnios and early gestational age (<26 weeks). Patients signed an informed consent. FST was performed with percutaneous injection of Ethamolin (ethanolamine oleate) or Polidocanol (aethoxysklerol) under ultrasound guidance using a 22-gauge needle. Results: Resolution of hydrops and of the mass effect was observed in all cases without any complications. All patients were delivered at term. Conclusions: Fetal sclerotherapy is a novel approach to the management of complicated type II-III CCAM. Further studies are indicated to assess the risks and benefits of this innovative technique.

KW - Cystic congenital adenomatoid malformation

KW - Ethamolin (ethanolamine oleate)

KW - Fetal hydrops

KW - Fetal therapy

KW - Lung mass

KW - Polidocanol (aethoxysklerol)

KW - Ultrasound

UR - http://www.scopus.com/inward/record.url?scp=50049125834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50049125834&partnerID=8YFLogxK

U2 - 10.1159/000151345

DO - 10.1159/000151345

M3 - Article

C2 - 18753764

AN - SCOPUS:50049125834

VL - 24

SP - 237

EP - 240

JO - Fetal Diagnosis and Therapy

JF - Fetal Diagnosis and Therapy

SN - 1015-3837

IS - 3

ER -